Page 13«..10..12131415..2030..»

Category Archives: MS Treatment

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform – Business Wire

Posted: Published on May 12th, 2021

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced it has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma Inc. ASP3652 complements Autobahns brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversion to enable delivery of small molecules across the blood brain barrier. Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahns compounds and enhances the ability to tailor a drugs biodistribution to match the pathophysiology of various disorders. Continue reading

Posted in MS Treatment | Comments Off on Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform – Business Wire

Workington mum needs 50,000 for vital MS treatment | News and Star – News & Star

Posted: Published on May 12th, 2021

A mother from Workington is appealing for people to help her raise funds for life-changing surgery in Mexico. Brogan Johnston, 26, has set up a go fund me page to try and raise the 50,000 she needs to receive treatment for Multiple Sclerosis after she was diagnosed earlier this year Continue reading

Posted in MS Treatment | Comments Off on Workington mum needs 50,000 for vital MS treatment | News and Star – News & Star

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme Launch – GlobeNewswire

Posted: Published on May 12th, 2021

JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. Continue reading

Posted in MS Treatment | Comments Off on SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme Launch – GlobeNewswire

Pandemic gets the Michael Lewis treatment – Business Standard

Posted: Published on May 12th, 2021

Theres nobody Michael Lewis likes better than a hero who gives a defiant middle finger to the conventional wisdom: The short-seller who bets against a soaring mortgage market; the equities trader who insists that the stock exchange is rigged. And then theres Mr Lewis himself, who has made his own name and fortune by writing against expectations, taking arcane subjects that most of his mega-readership might know next to nothing about and skilfully unfurling their intricacies in all of their dramatic glory. Continue reading

Posted in MS Treatment | Comments Off on Pandemic gets the Michael Lewis treatment – Business Standard

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study – DocWire News

Posted: Published on May 12th, 2021

This article was originally published here Brain Pathol. Continue reading

Posted in MS Treatment | Comments Off on CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study – DocWire News

TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsConference call to be held today, Monday, May 10, 2021 at…

Posted: Published on May 12th, 2021

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ending March 31, 2021 and recent company developments, along with a business outlook for 2021. Michael S. Continue reading

Posted in MS Treatment | Comments Off on TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsConference call to be held today, Monday, May 10, 2021 at…

Multiple Sclerosis Treatment Market To Generate Strong Revenue and Competitive Analysis The Courier – The Courier

Posted: Published on May 12th, 2021

TheMultiple Sclerosis Treatment MarketReport conveys the clean expounded structure of the Market including every single business-related data of the market at a worldwide level. The total scope of data identified with the Market is acquired through different sources and this got main part of data is orchestrated, handled, and spoken to by a gathering of authorities through the utilization of various methodological procedures and logical instruments, for example, SWOT analysis to produce an entire arrangement of exchange based examination in regards to the Multiple Sclerosis Treatment Market. Global multiple sclerosis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Continue reading

Posted in MS Treatment | Comments Off on Multiple Sclerosis Treatment Market To Generate Strong Revenue and Competitive Analysis The Courier – The Courier

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL – OncLive

Posted: Published on May 12th, 2021

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions. Continue reading

Posted in MS Treatment | Comments Off on Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL – OncLive

LogicBio Therapeutics Strengthens Management Team with Key Appointments – PRNewswire

Posted: Published on May 12th, 2021

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management Continue reading

Posted in MS Treatment | Comments Off on LogicBio Therapeutics Strengthens Management Team with Key Appointments – PRNewswire

Neuromyelitis Optica Treatment: Medications and More – Healthline

Posted: Published on February 5th, 2021

Neuromyelitis optica (NMO) is an autoimmune disorder that affects as many as 10 in 100,000 people, according to the National Organization for Rare Disorders. NMO is characterized by attacks on the optic nerves (optic neuritis) and spinal cord (transverse myelitis). Continue reading

Posted in MS Treatment | Comments Off on Neuromyelitis Optica Treatment: Medications and More – Healthline

Page 13«..10..12131415..2030..»